Journal Article

The Commission's <i>AstraZeneca</i> decision: delaying generic entry is an abuse of a dominant position

Sophie Lawrance and Pat Treacy

in Journal of Intellectual Property Law & Practice

Volume 1, issue 1, pages 7-9
Published in print November 2005 | ISSN: 1747-1532
Published online November 2005 | e-ISSN: 1747-1540 | DOI: http://dx.doi.org/10.1093/jiplp/jpi006
The Commission's AstraZeneca decision: delaying generic entry is an abuse of a dominant position

More Like This

Show all results sharing these subjects:

  • Arbitration
  • Intellectual Property Law

GO

Show Summary Details

Preview

The European Commission's recent AstraZeneca decision introduces abuse of the patent system as a novel type of infringement of Article 82 EC.

Journal Article.  1550 words. 

Subjects: Arbitration ; Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.